EGA
TENX icon

Eagle Global Advisors’s Tenax Therapeutics TENX Stock Holding History

Eagle Global Advisors’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1
Closed -$63K – 399
2015
Q1 		$63K Buy
+1
New +$105K ﹤0.01% 349

Other funds holding TENX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Global Advisors's TENX Position: Q2 2015 in Review

Eagle Global Advisors sold out of Tenax Therapeutics (TENX) in Q2 2015, closing a stake of 1 share — an estimated $63K sold.

Eagle Global Advisors first reported a position in TENX in Q1 2015 and held it in 1 quarter. The position peaked at $63K in Q1 2015. 16 funds tracked by Wall St. Rank hold TENX as of Q2 2015.

  • Eagle Global Advisors reported no remaining Tenax Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Eagle Global Advisors sold 1 Tenax Therapeutics share in Q2 2015, an estimated $63K.
  • Eagle Global Advisors first reported a position in Tenax Therapeutics in Q1 2015 and held it in 1 quarter.
  • Eagle Global Advisors's Tenax Therapeutics position peaked at $63K in Q1 2015.
  • 16 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2015.

Based on Eagle Global Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.